secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2021-11-15T23:59:59+00:00
Accession:  0000950170-21-004608
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q3 2021 net loss $14.0M; cash $135.4M post business combination
------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $135.4M as of Sept 30, 2021, up from $18.9M at June 30, 2021.
- Net loss of $14.0M for Q3 2021 vs $8.6M in Q3 2020; R&D expenses $10.4M (Q3 2021) vs $7.0M.
- Plan to initiate Phase 1a trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) in 2022.
- Pre-clinical data for both candidates presented at medical congresses; five new discovery programs initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017021004608/0000950170-21-004608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017021004608/srzn-20211110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-004608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer